Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CXCR3 | P49682 | 1/20 | 0.50 |
| ▸ | HDAC6 | Q9UBN7 | 3/20 | 0.43 |
| ▸ | CXCR4 | P61073 | 5/20 | 0.42 |
| ▸ | LTA4H | P09960 | 1/20 | 0.42 |
| ▸ | MEN1 | O00255 | 2/20 | 0.41 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.41 |
| ▸ | DRD2 | P14416 | 1/20 | 0.40 |
| ▸ | DRD1 | P21728 | 1/20 | 0.40 |
| ▸ | DRD4 | P21917 | 1/20 | 0.40 |
| ▸ | DRD5 | P21918 | 1/20 | 0.40 |
| ▸ | DRD3 | P35462 | 1/20 | 0.40 |
| ▸ | PRMT5 | O14744 | 1/20 | 0.40 |
| ▸ | WDR77 | Q9BQA1 | 1/20 | 0.40 |
| ▸ | HDAC1 | Q13547 | 3/20 | 0.40 |
| ▸ | HDAC3 | O15379 | 2/20 | 0.40 |
| ▸ | HDAC4 | P56524 | 2/20 | 0.40 |
| ▸ | HDAC8 | Q9BY41 | 2/20 | 0.40 |
| ▸ | HDAC5 | Q9UQL6 | 2/20 | 0.40 |
| ▸ | TP53 | P04637 | 1/20 | 0.39 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4929477 | 0.83 | CXCR4 (0.59) | HDAC6CXCR4LTA4HMEN1KMT2A | |
| SCHEMBL4929472 | 0.83 | CXCR4 (0.59) | HDAC6CXCR4LTA4HMEN1KMT2A | |
| SCHEMBL11935464 | 0.80 | JAK2 (0.46) | HDAC6CXCR4LTA4HMEN1KMT2A | |
| SCHEMBL13439203 | 0.80 | JAK2 (0.46) | HDAC6CXCR4LTA4HMEN1KMT2A | |
| SCHEMBL11934876 | 0.80 | ALDH1A1 (0.44) | HDAC6CXCR4LTA4HMEN1KMT2A | |
| SCHEMBL2394663 | 0.80 | CXCR3 (0.47) | CXCR3HDAC6CXCR4LTA4HMEN1 | |
| SCHEMBL13438751 | 0.80 | ALDH1A1 (0.44) | HDAC6CXCR4LTA4HMEN1KMT2A | |
| SCHEMBL11935114 | 0.78 | SPHK1 (0.51) | HDAC6LTA4HMEN1KMT2A | |
| SCHEMBL2393127 | 0.77 | CHEK1 (0.39) | HDAC6CXCR4MEN1KMT2AHDAC8 | |
| SCHEMBL20625942 | 0.77 | HDAC6 (0.49) | HDAC6CXCR4LTA4HMEN1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9073898-B2 | Crystalline form of an inhibitor of MDM2/4 and p53 interaction | NOVARTIS AG (CH) | 2015-07-07 | — | — | US | disclosed |
| US-9051279-B2 | Substituted isoquinolinones and quinazolinones | NOVARTIS AG (CH) | 2015-06-09 | — | — | US | disclosed |
| US-8969351-B2 | Crystalline form of an inhibitor of MDM2/4 and p53 interaction | NOVARTIS AG (CH) | 2015-03-03 | — | — | US | disclosed |
| EP-2640467-B1 | CRYSTALLINE FORM OF AN INHIBITOR OF MDM2/4 AND P53 INTERACTION | NOVARTIS AG (CH) | 2014-12-17 | — | — | EP | disclosed |
| EP-2516009-B1 | SUBSTITUTED ISOQUINOLINONES AND QUINAZOLINONES | NOVARTIS AG (CH) | 2014-09-24 | — | — | EP | disclosed |
| US-20130281473-A1 | SUBSTITUTED ISOQUINOLINONES AND QUINAZOLINONES | NOVARTIS AG (CH) | 2013-10-24 | — | — | US | disclosed |
| EP-2640467-A1 | CRYSTALLINE FORM OF AN INHIBITOR OF MDM2/4 AND P53 INTERACTION | Novartis AG (CH) | 2013-09-25 | — | — | EP | disclosed |
| US-20130245036-A1 | CRYSTALLINE FORM OF AN INHIBITOR OF MDM2/4 AND P53 INTERACTION | NOVARTIS AG (CH) | 2013-09-19 | — | — | US | disclosed |
| US-8440693-B2 | Substituted isoquinolinones and quinazolinones | NOVARTIS AG (CH) | 2013-05-14 | — | — | US | disclosed |
| EP-2516009-A1 | SUBSTITUTED ISOQUINOLINONES AND QUINAZOLINONES | Novartis AG (CH) | 2012-10-31 | — | — | EP | disclosed |
| WO-2012066095-A1 | CRYSTALLINE FORM OF AN INHIBITOR OF MDM2/4 AND P53 INTERACTION | NOVARTIS AG (CH) | 2012-05-24 | — | — | WO | disclosed |
| US-20120129871-A1 | Crystalline form of an inhibitor of MDM2/4 and p53 interaction | NOVARTIS AG (CH) | 2012-05-24 | — | — | US | disclosed |
| US-20110230457-A1 | Substituted Isoquinolinones and Quinazolinones | NOVARTIS AG (CH) | 2011-09-22 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110230457-A1 | Substituted Isoquinolinones and Quinazolinones | MDM4, MDM2, TP53 | CXCR3 1898/4885HDAC6 1090/4885CXCR4 475/4885 |
| US-20130245036-A1 | CRYSTALLINE FORM OF AN INHIBITOR OF MDM2/4 AND P53 INTERACTION | MDM4, TP53, TP53BP1 | CXCR3 4407/4885HDAC6 1856/4885CXCR4 2762/4885 |
| US-20130281473-A1 | SUBSTITUTED ISOQUINOLINONES AND QUINAZOLINONES | MDM4, MDM2, TP53 | CXCR3 1898/4885HDAC6 1090/4885CXCR4 475/4885 |
| US-20120129871-A1 | Crystalline form of an inhibitor of MDM2/4 and p53 interaction | MDM4, TP53, TP53BP1 | CXCR3 4401/4885HDAC6 1725/4885CXCR4 2730/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.